reported that MAPK signaling was found active in over half of clinical angiosarcoma samples, and combined inhibition of the VEGF and MAPK pathways with cediranib and trametinib had an additive effect in angiosarcoma (41). The gene discussed is VEGFA; the disease is angiosarcoma.